P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

por Beauvais, D., Sourisseau, M., Béhal, H., Alfandari, S., Simon, N., Faure, E., Yakoub-Agha, I.
Publicado 2022